Brokerages Expect Agenus Inc (AGEN) to Post -$0.30 EPS

Equities research analysts predict that Agenus Inc (NASDAQ:AGEN) will post earnings of ($0.30) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Agenus’ earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.28). Agenus reported earnings of ($0.42) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The business is scheduled to issue its next earnings report before the market opens on Thursday, May 9th.

According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.26) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($1.11). For the next year, analysts forecast that the firm will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.56) to ($0.84). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Agenus.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, March 14th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.12). The firm had revenue of $5.36 million for the quarter, compared to the consensus estimate of $6.67 million.

A number of research firms have recently weighed in on AGEN. ValuEngine upgraded shares of Agenus from a “hold” rating to a “buy” rating in a report on Thursday, January 17th. Zacks Investment Research lowered shares of Agenus from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. BidaskClub lowered shares of Agenus from a “buy” rating to a “hold” rating in a report on Friday, January 25th. Finally, B. Riley began coverage on shares of Agenus in a report on Monday, April 22nd. They set a “buy” rating and a $5.00 target price for the company.

Institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Agenus by 272.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock worth $76,000 after buying an additional 23,493 shares during the period. Metropolitan Life Insurance Co. NY purchased a new stake in Agenus in the fourth quarter worth about $80,000. Vanguard Group Inc lifted its holdings in Agenus by 0.4% in the third quarter. Vanguard Group Inc now owns 4,360,495 shares of the biotechnology company’s stock worth $9,332,000 after buying an additional 18,304 shares during the period. Bank of New York Mellon Corp lifted its holdings in Agenus by 26.6% in the fourth quarter. Bank of New York Mellon Corp now owns 442,886 shares of the biotechnology company’s stock worth $1,055,000 after buying an additional 92,957 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in Agenus by 26.7% in the third quarter. Wells Fargo & Company MN now owns 941,284 shares of the biotechnology company’s stock worth $2,015,000 after buying an additional 198,247 shares during the period. Institutional investors and hedge funds own 28.56% of the company’s stock.

Shares of Agenus stock traded down $0.03 during trading on Friday, reaching $2.61. 13,125 shares of the stock were exchanged, compared to its average volume of 1,446,022. The firm has a market cap of $354.44 million, a P/E ratio of -1.82 and a beta of 1.96. Agenus has a 1 year low of $1.54 and a 1 year high of $3.88.

About Agenus

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

See Also: What does relative strength index mean?

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.